About - INCY :

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Employees - 2524, CEO - Mr. Herve Hoppenot, Sector - Healthcare, Country - US, Market Cap - 13.61B

Altman ZScore(max is 10): 5.17, Piotroski Score(max is 10): 6, Working Capital: $1307058000, Total Assets: $5012434000, Retained Earnings: $-1274093000, EBIT: 132134000, Total Liabilities: $1841214000, Revenue: $4075860000

AryaFin Target Price - $122.19 - Current Price $68.84 - Analyst Target Price $78.33

Stats & Key Metrics
TickerINCY
IndexS&P 500
Curent Price 68.84
Change2.65%
Market Cap13.61B
Average Volume2.05M
Income32.48M
Sales4.08B
Book Value/Share16.45
Cash/Share8.97
Dividend Est-
Dividend TTM-
Dividend Ex-Date-
Employees2524
Moving Avg 20days-4.38%
Moving Avg 50days-4.69%
Moving Avg 200days8.70%
Shares Outstanding192.80M
Earnings DateOct 29 BMO
Inst. Ownership96.19%
Key Ratios & Margins
Price/Earnings487.54
Forwad P/E11.63
PE Growth15.66
Price/Sales3.34
Price/Book4.19
Price/Cash7.67
Price/FCF443.45
Quick Ratio1.82
Current Ratio1.87
Debt/Equity0.01
Return on Assets0.57%
Return on Equity0.80%
Return on Investment1.02%
Gross Margin91.21%
Ops Margin-0.30%
Profit Margin0.80%
RSI42.13
BETA(β)0.71
From 52week Low36.72%
From 52week High-18.00%
Earnings & Valuation
EPS0.14
EPS next Year5.92
EPS next Qtr1.51
EPS this Year-64.22%
EPS next 5 Year31.14%
EPS past 5 Year38.99%
Sales past 5 Year14.55%
EPS Y/Y-91.22%
Sales Y/Y12.94%
EPS Q/Q-28.22%
Sales Q/Q23.81%
Sales Surprise5.53%
EPS Surprise1.79%
ATR(14)2.26
Perf Week0.42%
Perf Month-3.11%
Perf Quarter7.36%
Perf Year13.30%
Perf YTD9.64%
Target Price78.33

AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer